Treating Bipolar 1 Disorder

By: 3BL Media

Healthcare professionals share perspectives on providing care for people living with bipolar 1 disorder

SOURCE: Alkermes

DESCRIPTION:

Check out a new infographic with findings from our latest survey conducted in partnership with The Harris Poll and Depression and Bipolar Support Alliance – National Headquarters. Learn what healthcare providers (HCPs) had to say about treating individuals with bipolar 1 disorder: https://bit.ly/383gMvq

About Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Tweet me: .@Alkermes has created a new infographic from findings with @HarrisPoll and @DBSAlliance on what healthcare providers (HCPs) had to say about treating individuals with #bipolar 1 disorder: https://bit.ly/3FPKj8a

KEYWORDS: NASDAQ: ALKS, Alkermes

Text: Treating Bipolar 1 Disorder, Healthcare Professionals Share Perspectives on Providing Care for People Living with Bipolar 1 Disorder

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  228.01
+0.66 (0.29%)
AAPL  271.88
-1.79 (-0.65%)
AMD  214.86
+1.43 (0.67%)
BAC  56.01
+0.73 (1.33%)
GOOG  310.79
+2.18 (0.71%)
META  659.16
+0.39 (0.06%)
MSFT  486.03
+0.11 (0.02%)
NVDA  183.21
+2.22 (1.22%)
ORCL  196.66
+4.69 (2.44%)
TSLA  494.62
+13.42 (2.79%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.